SCHEMBL5582554

SCHEMBL5582554

CN(C)CC1=Cc2ccc(C(=O)Nc3ccc(-c4ccc(F)cc4)cc3)cc2CC1

nearest known ligand 0.72

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 19/20 0.72
HTR2C P28335 1/20 0.63
PTPN1 P18031 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5582546 0.95 MCHR1 (0.80) MCHR1HTR2C
SCHEMBL5583062 0.86 MCHR1 (0.67) MCHR1HTR2CPTPN1
SCHEMBL5582892 0.86 MCHR1 (0.67) MCHR1
SCHEMBL5582702 0.85 MCHR1 (0.82) MCHR1HTR2C
SCHEMBL14454799 0.85 MCHR1 (0.82) MCHR1HTR2C
SCHEMBL14454853 0.85 MCHR1 (0.66) MCHR1HTR2CPTPN1
SCHEMBL5582822 0.84 MCHR1 (0.77) MCHR1HTR2C
SCHEMBL5582637 0.84 MCHR1 (0.70) MCHR1HTR2C
SCHEMBL5994627 0.84 MCHR1 (1.00) MCHR1HTR2C
SCHEMBL5582675 0.79 MCHR1 (0.71) MCHR1HTR2CPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-7115750-B1 Melanin concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173498-A1 Melanin concentrating hormone antagonist MC1R, MCHR1, MCHR2 MCHR1 2/4885HTR2C 195/4885PTPN1 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.